Skip to main content Accessibility help
×
Home

Adverse effects of antipsychotics as outcome measures

  • Samantha Hamer (a1) and Peter M. Haddad (a2)

Abstract

Background

Antipsychotic drugs are associated with adverse effects that can lead to poor medication adherence, stigma, distress and impaired quality of life

Aims

To review the use of adverse effects of antipsychotic drugs as outcome measures, with a particular emphasis on methodological issues

Method

Review of data on adverse effects from sources including randomised controlled trials (RCTs), post-marketing surveillance and naturalistic studies

Results

All have advantages and disadvantages and the best overview comes from considering all sources of data together. Adverse effects are inconsistently reported, hampering cross-study comparisons. Many outcome measures lack clinical meaning. In both naturalistic studies and RCTs adverse effects often account for less treatment discontinuation than lack of efficacy

Conclusions

Standardisation in the reporting of adverse effects is needed. Patients' subjective experience of medication should be given more consideration. Total discontinuation rates provide a useful global outcome measure that incorporates tolerability and efficacy as well as patient and clinician viewpoints. Patients should be informed of common side-effects prior to treatment and monitored for their occurrence during treatment

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Adverse effects of antipsychotics as outcome measures
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Adverse effects of antipsychotics as outcome measures
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Adverse effects of antipsychotics as outcome measures
      Available formats
      ×

Copyright

Corresponding author

Dr P. M. Haddad, Cromwell House, Cromwell Road, Eccles, Salford, Manchester M30 0GT, UK. Email: peter.haddad@bstmht.nhs.uk

Footnotes

Hide All

Declaration of interest

P.M.H. has received honoraria from several pharmaceutical companies.

Footnotes

References

Hide All
Ahmer, S., Arya, P., Anderson, D., et al (2005) Conflict of interest in psychiatry. Psychiatric Bulletin, 29, 302304.
Angermeyer, M. C., Loffler, W., Muller, P., et al (2001) Patients' and relatives' assessment of clozapine treatment. Psychological Medicine, 31, 509517.
Awad, A. G. & Hogan, T. P. (1994) Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatrica Scandinavica Supplementum, 380, 2732.
Bagnall, A. M., Jones, L., Ginnelly, L., et al (2003) A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment, 17, 1193.
Barnes, T. R. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672676.
Boutron, I., Estellat, C. & Ravaud, P. (2005) Areview of blinding in randomized controlled trials found results inconsistent and questionable. Journal of Clinical Epidemiology, 58, 12201226.
Chouinard, G., Ross-Chouinard, A., Annable, L., et al (1980) Extrapyramidal rating scale. Canadian Journal of Neurological Sciences, 7, 233239
Collegium Internationale Psychiatriae Scalarum (1986) International Scales for Psychiatry (4th edn). Hogrefe.
Day, J. C., Wood, G., Dewey, M., et al (1995) A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry, 166, 650653.
Day, J. C., Kinderman, P. & Bentall, R. (1998) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica, 97, 9397.
Dursun, S., Haddad, P. M. & Barnes, R. E. T. (2004) Extrapyramidal syndromes. In Adverse Syndromes and Psychiatric Drugs (eds P. M. Haddad, S. Dursun, & B. Deakin), pp. 120. Oxford University Press.
Fakhoury, W. K., Wright, D. & Wallace, M. (2001) Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. International Clinical Psychopharmacology, 16, 153162.
Fontanarosa, P. B., Rennie, D. & DeAngelis, C. D. (2004) Postmarketing surveillance – lack of vigilance, lack of trust. JAMA, 292, 26472650.
Frank, A. F. & Gunderson, J. G. (1990) The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Archives of General Psychiatry, 47, 228236.
Franz, M., Lis, S., Pluddemann, K., et al (1997) Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry, 170, 422425.
Fung, M., Thornton, A., Mybeck, K., et al (2001) valuation of the characteristics of the safety withdrawals of prescription drugs from worldwide pharmaceutical markets – 1960 to 1999. Drug Information Journal, 35, 293317.
Geddes, J., Freemantle, N., Harrison, P., et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 13711376.
Gough, S. (2005) Post-marketing surveillance: a UK/European perspective. Current Medical Research and Opinion, 21, 565570.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (Revised), pp. 534537. U.S. Department of Health, Education, and Welfare.
Haddad, P. (2005) Weight change with atypical antipsychotics in thetreatment of schizophrenia. Journal of Psychopharmacology, 19 (suppl.), 1627.
Haddad, P. M. & Anderson, I. M. (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62, 16491671.
Haddad, P. M. & Dursun, S. (2006) Selecting antipsychotics in schizophrenia: lessons from CATIE. Journal of Psychopharmacology, 20, 332334.
Haro, J. M. & Salvador-Carulla, L. (2006) The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs, 20, 293301.
Haro, J. M., Suarez, D., Novick, D., et al (2007) Three-year antipsychotic effectivenessin the outpatient care of schizophrenia: observational versus randomized studies results. European Neuropsychopharmacology, 17, 235244.
Hasler, G., Moergeli, H., Bachmann, R., et al (2004) Patient satisfaction with outpatient psychiatric treatment: the role of diagnosis, pharmacotherapy, and perceived therapeutic change. Canadian Journal of Psychiatry, 49, 315321.
Heinrichs, D. W., Hanlon, T. E. & Carpenter, W. T. (1984) The Quality of Life Scale: an instrument for rating schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388398.
Hodgson, R., Belgamwar, R., Al-tawarah, Y., et al (2005) The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire. Human Psychopharmacology, 20, 141147.
Hogan, T. P., Awad, A. G. & Eastwood, R. (1983) A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative ability. Psychological Medicine, 13, 177183.
Jones, P. B., Barnes, T. R., Davies, L., et al (2006) Randomised controlled trial of the effecton Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugsin Schizophrenia Study (CUtLASS I). Archives of General Psychiatry, 63, 10791087.
Kikkert, M. J., Schene, A. H., Koeter, M. W. J. et al (2006) Medication adherencein schizophrenia: exploringpatients', carers'and professionals' views. Schizophrenia Bulletin, 32, 786794.
Kinon, B. J., Liu-Seifert, H., Adams, D. H., et al (2006) Differential rates of treatment discontinuation in clinical trials as ameasure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. Journal of Clinical Psychopharmacology, 26, 632637.
Labbate, L. A. & Lare, S. B. (2001) Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychotherapy and Psychosomatics, 70, 221225.
Leucht, S., Wahlbeck, K., Hamann, J., et al (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 361, 15811589.
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353 12091223.
Lingjaerde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and across-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum, 76, 1100.
Mann, R. D. (1998) Prescription-event monitoring –recent progress and future horizons. British Journal of Clinical Pharmacology, 46, 195201.
McGahuey, C. A., Gelenburg, A. J., Laukes, C. A., et al (2000) The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sexand Marital Therapy, 127, 2540.
Mitra, S. & Haddad, P. M. (2007) Documentation of extrapyramidal symptoms. Psychiatric Bulletin, 31, 7677.
Morgenstern, H. & Glazer, W. M. (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry, 50, 723733.
Ogundipe, L. O., Boardman, A. P. & Masterson, A. (1999) Randomisation in clinical trials. British Journal of Psychiatry, 175, 581584.
Rao, D., Zajecka, J. & Skubiak, T. (2005) The Modified Rush Sexual Inventory: preliminary psychometric findings. Psychiatry Research, 137, 175181.
Simpson, G. M. & Angus, J. W. S. (1970) Arating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212, 1119.
Swartz, M. S., Perkins, D. O., Stroup, T. S., et al (2007) Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry, 164, 428436.
Thornicroft, G., Tansella, M., Becker, T., et al (2004) Thepersonal impact of schizophreniain Europe. Schizophrenia Research, 69, 125132.
Tiihonen, J., Walhbeck, K., Lonnqvist, J., et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, 333, 224.
Voruganti, L., Cortese, L., Oyewumi, L., et al (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference totheir subjective tolerability, side-effect profile and impacton quality of life. Schizophrenia Research, 43, 135145.
Wieck, A. & Haddad, P. M. (2003) Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. British Journal of Psychiatry, 182, 199204.

Related content

Powered by UNSILO

Adverse effects of antipsychotics as outcome measures

  • Samantha Hamer (a1) and Peter M. Haddad (a2)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Adverse effects of antipsychotics as outcome measures

  • Samantha Hamer (a1) and Peter M. Haddad (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *